One-Patient trial tests hope for devastating rare disease
NCT ID NCT05998395
Summary
This study tested an oral drug called ruxolitinib in a single adult patient with a rare, severe disease that damages blood vessels in the brain and spinal cord. The goal was to see if the drug could stop the disease from getting worse by preventing new brain lesions. The patient took the drug for up to 26 weeks while doctors closely monitored their condition with scans and tests.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KOHLMEIER-DEGOS DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.